Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 69 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MnfCSpVv[3Srb36gRZN{[Xl? Moj0NE44|ryP M{TqOFI1cA>? NW\KXFVw\XSqYX7vcC=> M4TzNIVvcGGwY3XzJGVP[UNiYXPleJlt[XSrb36gZY5lKGmwY4LlZZNmeyCHTnHDJIFjfW6mYX7j[UBqdiC2aHWgeI91[WxiY3XscEBtgXOjdHWgZY5lKGG2IITo[UBk\WyuIIP1doZi[2V? MYWyOVc5PzB5OR?=
TE13 M4DGVGZ2dmO2aX;uJGF{e2G7 NVXZSYRbOC5|zszN M3nPdVI1cA>? M3\tWJVxNXKnZ4XsZZRmeyCUQWPTSlVCKGyndnXs NGPJTogzPTV5OU[2OS=>
TE13 NXPaPIdTSXCxcITvd4l{KEG|c3H5 NVXjeJVTOC5|zszN NIftfokzPGh? MYXpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v MkHqNlU2Pzl4NkW=
MEFs M3jOPGZ2dmO2aX;uJGF{e2G7 MWi1{txO M{P6WlE3cA>? NYLtfodzcW6lcnXhd4V{KHSqZTDFVGVEKGG2dHHjbI1mdnRuIGTpdkBl\WyrdnXyfUBidmRidHjlJIVn\mmlaXXuZ5khd2ZicHXk[ZN1[WxiZn;ycYF1cW:w NYPqblZ5OjV2OEK2N|Q>
SW480  Mkj4SpVv[3Srb36gRZN{[Xl? MlzvNE4y|ryP MYG0PIg> MljKSG1UVw>? M4nreZJmfmW{c3XzJGVOXA>? MXmyOVQ{PDl7Nx?=
PC3  NViyPXpxTnWwY4Tpc44hSXO|YYm= Mn3lNE4y|ryP NIXRWGg1QGh? MVzEUXNQ MVvy[ZZmenOnczDFUXQ> NV\yV4lSOjV2M{S5PVc>
SW480  M4jCZmZ2dmO2aX;uJGF{e2G7 NIPhUWwxNjIQvF2= NX7iXWhYPDiq MX7EUXNQ NYrVb5NL[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u MmXrNlU1OzR7OUe=
PC3  MU\GeY5kfGmxbjDBd5NigQ>? NHHo[JoxNjIQvF2= MVi0PIg> MYDEUXNQ MU\heJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? M1vWRVI2PDN2OUm3
SW480  M1vTW2Z2dmO2aX;uJGF{e2G7 M3L0SlAvOc7:TR?= MWC0PIg> M4S1NmROW09? NX6wSYhucW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= MnjDNlU1OzR7OUe=
PC3  NHH3UHBHfW6ldHnvckBCe3OjeR?= MlOwNE4y|ryP NIjNRZM1QGh? MoL6SG1UVw>? MkO0bY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? M2SwV|I2PDN2OUm3
A431 Ml;ORZBweHSxc3nzJGF{e2G7 NF2y[G4zNzFyL{WwM|ExOG6P M4LqRlQ5cA>? MnOwSG1UVw>? MmDtbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3Sq MWiyOVM4OTB4OR?=
A431 NIn6[nlHfW6ldHnvckBCe3OjeR?= NEC1doY2OG6P M3;VT|IwPi9zMj:yOIg> NGHjfIxFVVOR Mn[yZYN1cX[jdHXzJJAzOSCjbnSgbY5pcWKrdIOgRXRHOyCneIDy[ZN{cW:w Ml\sNlU{PzFyNkm=
MDA-MB-231 M2DseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmezNE03ODCwTR?= MYqyOIg> NIHLOpdFVVOR Mn\nTWM2OCCxZjCxNFBvVQ>? M33EUlI2OTl{N{Kx
MCF7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz6bo4xNTZyMH7N NWXNdmozOjSq M1;CXGROW09? MWHJR|UxKG:oIEe1cm0> NGfsSnczPTF7MkeyNS=>
SKOV-3 M37KPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml71NU0yOM7:TR?= MnXyNlRp NETEUWZFVVOR NILMO5JKSzVyIH;mJFUvPs7:TR?= MmTrNlUyPjl2OUG=
A549 NIfONnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3mxZVEuOTEQvF2= MYGyOIg> NG\TUFlFVVOR NYe4PXQ{UUN3MDDv[kA{NjMQvF2= NV3ncYdWOjVzNkm0PVE>
SKOV-3 M4HWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLSNE4yNTIQvF2= NEm2NJI1QGh? MkOxSG1UVw>? NEfPdm9KSzVyIH;mJFAvP87:TR?= M1nudlI2OTZ7NEmx
A549 NISyS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTsUo5[OC5zLUJOwG0> MknPOFhp MVnEUXNQ M4PvbmlEPTBib3[gNE4zQM7:TR?= M1fYe|I2OTZ7NEmx
SKOV-3 Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKwMlAyNTBwOd88US=> M2TXWFczcA>? MkDLSG1UVw>? M1jRUmlEPTBib3[gNE4{Os7:TR?= Ml\nNlUyPjl2OUG=
A549 NGXzRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXVPWkxNjBzLUCuPe69VQ>? M2X6fFczcA>? MULEUXNQ M{D6XWlEPTBib3[gNE4xPs7:TR?= NYT5ZlE4OjVzNkm0PVE>
HeLa NHTwVnVHfW6ldHnvckBCe3OjeR?= NFK4S3IzPTCwTR?= NWCwVG1FOT[q MVrEUXNQ MV3pcoNz\WG|ZYOgR3lROUFzIH3SUmEh\XiycnXzd4lwdsLi MljSNlUyOTZ4OEi=
CNE2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjod2MyODBvNkCwcm0> NYjUOGJzOjRxNEivO|Jp MV7pcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXPiS3F7OjR7Nkm5NFE>
PC3 MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn5OY8yODBvMUCwNI5O NGXrVZkzPGh? NGjo[IZKSzVyIH;mJFMxOG6P NIHtdo4zPDh3NE[1PC=>
LNCaP MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXexNFAuOTByMH7N MoG1NlRp NFvyU5dKSzVyIH;mJFMxOG6P NIHM[lUzPDh3NE[1PC=>
HeLa  MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHqdWROOs7:TR?= NVvQWWhIPDiq Mmft[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHHic5V1KDJ3JR?= M1OySFI1QDR4MUO1
HMEC-1  NHX1c4pHfW6ldHnvckBCe3OjeR?= M1\Ze|MxOG6P MXqyOIg> Mn;xbY5kemWjc3XzJIV5eHKnc4Ppc44hd2cEoG\FS2ZTO8LibWLORS=> MnHoNlQ4OTB4M{G=
HeLa MXrGeY5kfGmxbjDBd5NigQ>? NYCx[ZVROW2P MYKwMlVp Ml32ZYJwdGm|aHXzJJRp\SC2b4ThcEBJTEGFIHHjeIl3cXS7 MYqyOFcxPzR5NB?=
ACP02 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke4NlUxNzN3MD:1NFBvVQ>? NFvxflEzPGh? M2C1T4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? Mm\oNlQ3Pjh3NEe=
ACP03 M3Xrdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWqyOVAwOzVyL{WwNI5O MVGyOIg> NXTqO4Yz\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JI9nKGGycILvfIlu[XSnbImgO|DDqCViYYSgNlUxyqCwTR?= NUfoVYNQOjR4Nki1OFc>
U87 GBM NH3Le|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSxNFAwOzByL{WwNEBvVQ>? MXm3NkBp NHe5RZUyODBnIHX0bIFvd2x? Moq2doVlfWOnczDt[YFvKGOnbHygcpVu[mW{IHL5JFMyNCB3NDygZY5lKDV6wrCl M2Xkc|I1PDZ2OESx
U87 GBM NYXZdWJvTnWwY4Tpc44hSXO|YYm= NIHJcXIyODBxNUCwJG5u NX;md3hNPDhiaB?= NHGxRpYyODBnIHX0bIFvd2x? MW\JcoR2[2W|IGPlcoV{[2WwY3WtUIls\SCDbITldoF1cW:wczDpckBPfWOuZXHyJG1wenCqb3zv[5k> MV6yOFQ3PDh2MR?=
RPE M1vsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofWNE4zNzBwND:wMlgwOSEQvF2= M2D0Z|I1NzR6L{eyJIg> MWTEUXNQ NYrsfGZGcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R? NGXOOoIzPDR3Nk[wNi=>
HT29  M{TU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnpNVgxKG6P M1y5V|czKGh? M1XV[WlEPTBib3[gNVgxKG6P NXfJOnpLOjR|NkiyOlU>
hMSCs MU\GeY5kfGmxbjDBd5NigQ>? NGTOVZE3NjJ3IH7N NFXDZmYzPCCq NYOyUIpJTE2VTx?= NWXrc4lje3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=> MUCyOFMyOjN3Nh?=
Huh7  NETYXopHfW6ldHnvckBCe3OjeR?= NUnrVXdIOC5zL{CuOU8yNjBizszN NYLn[oN4OjSq NEn0Z3h{fXCycnXzd4V{KFmWSFTDNkBo\W6nIHX4dJJme3Orb36= MkfUNlQzPjl4N{K=
SKOV3 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIflPHQxNjB3LUKg{txO MUCxNE8zPC92ODDo MnyxSG1UVw>? NUHTTWZudWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NI\NUHkzPDJ{M{iwNS=>
A2780 M3TuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rRWlAvODVvMjFOwG0> NYKweGdkOTBxMkSvOFghcA>? M4jtZ2ROW09? MkTGcYVlcWG2ZYOg[5Jwf3SqIHHydoV{fCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M1rsfFI1OjJ|OECx
SRA01/04  NUnSXXJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\qOYU{OC5{IN88US=> NUfKdox[PDhiaB?= Mmi2SG1UVw>? NYrYdJl4e3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? MUGyOFE2Pzh5OB?=
HLEB3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXRR3FROC5{IN88US=> NYHQNXN5PDhiaB?= M1iyVWROW09? NHuyNWx{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? NGr4dnQzPDF3N{i3PC=>
SRA01/04  M4O5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\UNE41NzBwODFOwG0> M1r3ZlQ5KGh? NID6fopFVVOR NETpV3RqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NFrY[W0zPDF3N{i3PC=>
HLEB3 Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDHNZkxNjRxMD64JO69VQ>? MXm0PEBp NIXoemJFVVOR MnXlbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MoTQNlQyPTd6N{i=
HCT116 M3z1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTHOIl3OC5{IN88US=> NHK5cocyOiCq MUPlcohidmOnczDj[YxtKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IILh[IlifGmxbh?= NYrkWJJ{OjRzMkKyN|E>
CA46 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W3dFMwPi9zMj:yOE81QCCwTR?= NH7lZXc1QCCq NG[z[G9qdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHH0JFI1KGGwZDC0PEBvVcLi MkfFNlQxPjR7NUG=
PMNs NInmdnBHfW6ldHnvckBCe3OjeR?= Ml;YN|Ahdk1? NVHveFFsPDhiaB?= NXzXTXFjcW6qaXLpeJMh\W[oZYLvZ5l1d3OrczygTGRCSyCjY4Tpeol1gSCjbnSgVoFkKGGldHn2bZR6 NY\EfWNMOjN7OEi2NVc>
H1299 Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvESJI3OcLizszNxsA> MYOyOE81QC95MjDo MoTC[ZRp[W6xbB?= NU\P[mhicW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq Moq1NlM6OTZ4MEm=
A549 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqwMlI2NzBwNT:xJO69VQ>? MojlNlQwPDhxN{KgbC=> NVjQeYgz\XSqYX7vcC=> NX\UV5h6cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NYDnTnR1OjN6Nke5PVE>
H1299 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOwMlI2NzBwNT:xJO69VQ>? MVWyOE81QC95MjDo NWS3W5RO\XSqYX7vcC=> MnKxbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M2TDVlI{QDZ5OUmx
A549 MkLBRZBweHSxc3nzJGF{e2G7 MoDFNE42NzFizszN MYe0PEBp MUfleIhidm:u NYDaUZJxcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NV;qdXNXOjN6Nke5PVE>
H1299 NEW5Z2VCeG:ydH;zbZMhSXO|YYm= M{fISFAvPS9zIN88US=> MWS0PEBp NVe2RXVH\XSqYX7vcC=> MXLpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVOyN|g3Pzl7MR?=
SUM149PT MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP1Nk84NjVxMUCg{txO NHrwfZY1QCCq NF3XbIFFVVOR NVjZeHlJcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEKg{txOKGmwc3Xud4l1cX[nbIm= MYOyN|c6OjZ|OB?=
SUM190PT NYH4RoMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmCxOVAwOTByL{K1NEBvVQ>? NXrBS5V6PDhiaB?= NVfY[HgxTE2VTx?= NXrwPJV7cW6mdXPld{Bk\WyuIHTlZZRpKGG2IEWwJI5OKHOnboPpeIl3\Wy7 M4f6UFI{Pzl{NkO4
HCT1 Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLzWYZkOC5{L{GuNE82NjBizszN MV6xNk8zPC9|Nj:0PEBp M2TWOIlv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MYqyN|c4ODByMB?=
Lovo NIGzbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\MT|AvOi9zLkCvOU4xKM7:TR?= NGLiXokyOi9{ND:zOk81QCCq NU\HS2RJcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NXjTT25UOjN5N{CwNFA>
AGS Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[wMlAyPS1zIN88US=> NYP1VGdqPzJiaB?= NGD2XlJqdmS3Y3XzJINmdGxiZHXheIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> NWDRdYtnOjN5NEWwNlQ>
Huh7 M{P4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrofJEyKM7:TR?= MYiyOEBp MVnEUXNQ Mn;JdoVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> M1ftWFI{PjR|OUOz
ECC1 NYj1OYl6TnWwY4Tpc44hSXO|YYm= NHjzVlk2ODBibl2= NWfCcFlpPSCm NFfRTZlFVVOR Mnf1bY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NFiyNGgzOzV|MEe2PS=>
HEC1A M2T1WmZ2dmO2aX;uJGF{e2G7 NGDVWZY2ODBibl2= MmjNOUBl NFvLNmJFVVOR M2nSfolv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MWiyN|U{ODd4OR?=
EN1 NYLodXhbTnWwY4Tpc44hSXO|YYm= NISxc2I2ODBibl2= NV;uSFFLPSCm MkHMSG1UVw>? NEnubJBqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= M{fUOFI{PTNyN{[5
MFE296 M362WGZ2dmO2aX;uJGF{e2G7 MnmwOVAxKG6P M1y2S|Uh\A>? NWS1OGVUTE2VTx?= MX;pcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NH;YZY8zOzV|MEe2PS=>
HASMCs MWLGeY5kfGmxbjDBd5NigQ>? M4T3clAuPTByIH7N MWe2JIQ> MWfkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> MX:yN|UyQDR4Nx?=
U373 NGroSGpHfW6ldHnvckBCe3OjeR?= NF\XR48xNjJ3L{CuOU8yKM7:TR?= Mn7RNlQhcA>? Mk\ubY5kemWjc3XzJHBTNUJiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1RZpi\EN? MlnUNlM1PzRzN{G=
ARN8  MX\GeY5kfGmxbjDBd5NigQ>? NVPDe|hmOC5yNT2yJO69VQ>? NG\rb|UzPCCq MnfjdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> MYCyN|Q4ODV2MB?=
MCF7 MYnGeY5kfGmxbjDBd5NigQ>? M1fyOVAvODVvMjFOwG0> MmP6NlQhcA>? M3XVcpJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDwOVMu\GWyZX7k[Y51KGenbnXzJIJ6KE63dHzpck0{ NXzESoZmOjN2N{C1OFA>
H1299  M{TVU2Z2dmO2aX;uJGF{e2G7 NVi5W4o3OC5|M,MAl|HDqML3TR?= M2jjc|I1NzR6IHi= NUDERZlKTE2VTx?= M3vkT4lv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm= MVSyN|Q3OTl5NR?=
H1299 Ml75SpVv[3Srb36gRZN{[Xl? NUHXcW9jOC53IN88US=> MYC0PEBp NInofW1FVVOR NUD3OFVwcW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MonQNlM1PjF7N{W=
H1299 MnzGSpVv[3Srb36gRZN{[Xl? MWGwMlUh|ryP M3LSelQ5KGh? MnnLSG1UVw>? NFT6bJpqdmirYnn0d{B1cGViaX72ZZNqfmWwZYPzxsAh[2:vYnnu[UB4cXSqIIPpcIljcW6rbh?= MoiyNlM1PjF7N{W=
MG-63  M1ywNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jUZlAvOyEQvF2= MmLVNVIuQTZiaB?= MoXmSG1UVw>? NUL3fXpGcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> NEjlPJIzOzR3MUixOy=>
LM8 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSwMlMh|ryP MlvqNVIuQTZiaB?= NGXUTWlFVVOR NEXpWGNqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu NVizcZhuOjN2NUG4NVc>
K562 NX:xRnJzTnWwY4Tpc44hSXO|YYm= M1vqdFAvPSEQvF2= MV:yOEBp MnXP[ZRp[W6xbB?= NGTLWGVl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? MljNNlM1OzB7NUe=
HEL Mm\xSpVv[3Srb36gRZN{[Xl? NH7iVJgxNjVizszN MnnlNlQhcA>? Mor2[ZRp[W6xbB?= NHe3ZYNl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? M3\pfVI{PDNyOUW3
HL60 MnGzRZBweHSxc3nzJGF{e2G7 Mlf6NUDPxE1? NY\nfI1wOjRiaB?= NXzRWWlEcW6mdXPld:Kh[2WubDDk[YF1cA>? MYOyN|QxODVzOR?=
KG1 NWLXO4ZbSXCxcITvd4l{KEG|c3H5 NF3GNlUyKM7:TR?= NGjnO2IzPCCq MXvpcoR2[2W|wrDj[YxtKGSnYYTo NGToU2IzOzRyMEWxPS=>
Kazumi NIf6fGVCeG:ydH;zbZMhSXO|YYm= Ml7INUDPxE1? Mmm3NlQhcA>? M{LSPIlv\HWlZYRCpINmdGxiZHXheIg> NIP3bnozOzRyMEWxPS=>
K562 NEjHVVRCeG:ydH;zbZMhSXO|YYm= NIKw[HgyKM7:TR?= NEe1TWYzPCCq MlTobY5lfWOnc9MgZ4VtdCCmZXH0bC=> M1;5UFI{PDByNUG5
THP1 Moq1RZBweHSxc3nzJGF{e2G7 MVOxJO69VQ>? NGS5O5MzPCCq M4TxOolv\HWlZYRCpINmdGxiZHXheIg> M2\RSFI{PDByNUG5
SH-SY5Y M2\meGZ2dmO2aX;uJGF{e2G7 M13LXlI2OCCwTR?= NYDhXIVCOTZiaB?= MUTjbIFv\2W|IHX4dJJme3Orb36gdIF1fGW{bjDv[kBo\W6nczDpcpZwdH[nZDDpckBkcG:uZYP0[ZJwdCC|eX70bIV{cXNuIIXweIFs\SCjbnSg[YZndHW6 NV2wWFdGOjN|Mk[0NlI>
HEK293 NI\hTplHfW6ldHnvckBCe3OjeR?= NFvSdpYyKML3TdMg MUOxPEBpyqB? MkLibY5pcWKrdIOgeIhmKGujbHnybY4uPy2vZXTpZZRm\CC{ZXPyeYl1dWWwdDDv[kB{gW6yaHnsbY4uOSCjZ3fy[YdifGW|IHnueI8h[WepcnXzc41mew>? NHTsOnAzOzJ6NEi0PC=>
HTK MVrGeY5kfGmxbjDBd5NigQ>? MUG0NFAhdk1? MkLlO|IhcA>? NWjzWI9XcW6qaXLpeJMhXEeILd8y5qCUUW6mdXPl[EBOgW:oaXLyc4Jt[XO2IFTp[oZmemWwdHnheIlwdg>? NFjpdpIzOzJ6NECwNi=>
HTK NFfm[JBHfW6ldHnvckBCe3OjeR?= Mn;KNVAxNThyMH7N M3HnUlczKGh? MXHicI9kc3NiVFfGMe6z6oDVSX7keYNm\CCUT2OgZY5lKEh{T{NCpGFk[3WvdXzheIlwdg>? NF3XSWczOzJ6NECwNi=>
Caco-2  Mm\KSpVv[3Srb36gRZN{[Xl? Mn;3NUDDvU4EoB?= MYSyOEBp NVzmS3l4\GWlcnXhd4V{KFOHUmSgdJJwfGWrbjDlfJBz\XO|aX;u NH;iSoMzOzF7NUC3NC=>
HeLa M164b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXexNFAhdk1? M3TqWFI1KGh? NWrZdmZ2TE2VTx?= Ml3vTWM2OCCxZjCxNFBvVQ>? MnnQNlMyPjV5NEi=
HeLa NX;pWmQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXFOFAhdk1? MlnnOFghcA>? MkHWSG1UVw>? MXfJR|UxKG:oIESwcm0> NYXkN3dnOjNzNkW3OFg>
HeLa MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvyUXIzOCCwTR?= NEHuZXY4OiCq Ml[5SG1UVw>? Ml;aTWM2OCCxZjCyNI5O MmrONlMyPjV5NEi=
HeLa MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYexNE8{OC93MDDuUS=> Mn:1O|IhcA>? MmXjSG1UVw>? Mmm3bY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiTV3QJEjPnM7qbTmgcI9{eyClZXzsd{Bld3OnIHTldIVv\GWwdHz5 M{f5dFI{OTZ3N{S4
MDA-MB-231 Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvxeJRROjVvNECwJI5O NX3oZm53PDhiaB?= M37DOGlEPTBib3[gNlY{NjKwTdMg M3HueFI{ODV3MUm4
MCF-7  Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PJe|I2NTRyMDDuUS=> M4[3dVQ5KGh? M2PId2lEPTBib3[gNlIxNjSwTR?= NIH4[nIzOzB3NUG5PC=>
ECC-1  NWTO[WxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKxNFAhdk1? NV3HXnF6OjRiaB?= MWfleIhidm:u MkH6bY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn NYm0NZg6OjNyMki4NFM>
HEC-1A NUf4THdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXGxNFAhdk1? M2e4NlI1KGh? MVnleIhidm:u M33EO4lv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?= NYnnO4F3OjNyMki4NFM>
NHAC-kn M13wNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7XWJhiOTBxMUCwM|UxOCCwTR?= MWqxNkBp NFmxbYtFVVOR MnnrTWM2OCCxZjC1NFBvVQ>? M{HJblI{ODF5OEex
A549 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrOV4lROjVyIH7N MlPZOk04OiCq NYHPT5FETE2VTx?= NEnBVIVk[XW|ZYOgZUBoemWjdHXyJIlvcGmkaYTvdpkh\W[oZXP0JINwdWKrbnWge4l1cCCWWGSgc5Ih\XKub4Tpcolj Mn2zNlI6QTR5OEC=
MG-63 M17Nemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWewV41xOzByIH7N NEfm[XIyOiCq NVXyephsTE2VTx?= NH3DTnRqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hQDZn Mk\hNlI4QTl|M{i=
MG-63 Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXezNFAhdk1? MWSyOEBp NWS1S|hpTE2VTx?= NEHi[pZqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPjdn MVSyNlc6QTN|OB?=
MG-63 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnHXW1bOzByIH7N MWK0PEBp NGPIWpdFVVOR MYfpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOVYm M1X5cVIzPzl7M{O4
HL60  NHP4dYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXucXUyPTBvM{WwJI5O NXS4NHpsOjRiaB?= MnW2bY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> M2iwWFIzPzV|N{O5
U937 MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPsO|FmOTVyLUO1NEBvVQ>? MnrvNlQhcA>? Mk[4bY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> MVqyNlc2Ozd|OR?=
SCC-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDhV3YzODBvM{KwNEBvVQ>? MWSxNk8zPC92ODDo NYXXeHB5TE2VTx?= MWPpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NH:zPZkzOjV3MkOyNS=>
U87  NEO4fmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGxNFAuOzByIH7n MUCyOEBp MnXKbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFczLSBiYYSgNlAxdmd? M{HQcVIzOjdyOES5
K562 NGe0PZBHfW6ldHnvckBCe3OjeR?= NYXFb5d{OSEQvF2= M2rBXlEzKGh? M1nwcWROW09? M4\GeoVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS M3S4bVIzOTd7MUm4
Reh M{LuR2Z2dmO2aX;uJGF{e2G7 NGLhVlQxNjNxMTFOwG0> Mn\UNVIhcA>? M{XYd2ROW09? M4rNR4VvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS MVuyNlE4QTF7OB?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
EGFR / STAT3 ; 

PubMed: 31289542     


Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting.

Cyclin D1 / CDK6 / CDK4 / p-RB / RB; 

PubMed: 31289542     


Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. 

MMP-1 / MMP-3 / MMP-13 / TIMP-1; 

PubMed: 27431944     


Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h.

Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); 

PubMed: 27431944     


Chondrocytes were treated with increasing concentrations of TSA for 24 h.

α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; 

PubMed: 23802098     


Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).

31289542 27431944 23802098
Immunofluorescence
α-C/EBPβ / α-HP1α ; 

PubMed: 21122806     


3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. 

α-HDAC1 ; 

PubMed: 29045501     


MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels.

α-tubulin / acetylated histone 3; 

PubMed: 27957719     


Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.

21122806 29045501 27957719
Growth inhibition assay
Cell viability (A549 cells); 

PubMed: 27571418     


Cytotoxicity of histamine determined by MTT assay in A549 cells.

Cell viability (MDA-MB-231 cells); 

PubMed: 27548148     


The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8.

Cell viability (PC3 cells); 

PubMed: 31289542     


PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.

27571418 27548148 31289542
In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03901053 Not yet recruiting Device: Reaktiv AFO|Device: PhatBrace AFO Foot Injuries and Disorders Jason Wilken|Minneapolis Veterans Affairs Medical Center|Walter Reed National Military Medical Center|Henry M. Jackson Foundation for the Advancement of Military Medicine|Center for Veterans Research and Education|University of Delaware|Johns Hopkins Bloomberg School of Public Health|University of Iowa June 2019 Not Applicable
NCT03887650 Recruiting Drug: Liposomal Bupivicaine 1.3%|Drug: Bupivacaine 0.5% Post-operative Pain|Total Shoulder Arthroplasty|Osteoarthritis of the Shoulder|Pain Management Hartford Hospital January 14 2019 Phase 4
NCT03838926 Recruiting Drug: Trichostatin A Relapsed or Refractory Hematologic Malignancies Vanda Pharmaceuticals September 27 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID